Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor
England KS., Tumber A., Krojer T., Scozzafava G., Ng SS., Daniel M., Szykowska A., Che K., von Delft F., Burgess-Brown NA., Kawamura A., Schofield CJ., Brennan PE.
Compound 35 is a potent and selective triazolopyridine inhibitor of the lysine demethylase KDM2A (pIC50 7.2).